BioSpace News Archive

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg.

HCW Biologics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City.

A new physician-training system in telehealth simulates key parts of traditional, in-person neurological exams that use little reflex hammers, pinpricks, and flashlights to test nerve function.

QurAlis today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and frontotemporal dementia (FTD).

Aptose Biosciences Inc. announced closing of a $3 million investment in common shares of the Company as the first tranche of a private equity investment for up to a maximum of $7 million or 19.99 percent ownership interest by Hanmi Pharmaceutical, Inc., Seoul, South Korea.

Rani Therapeutics Holdings, Inc. today announced that Rani will participate in and present at two upcoming investor conferences in September 2023.

Immuneering Corporation today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy.

Candel Therapeutics, Inc. today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City.

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.

IN8bio, Inc.today announced William Ho, CEO and co-founder, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 2:00 p.m. ET.